SjDCCR1Post

1. What are limitations of previous clinical trials studying improvement in Sjogren’s disease (SjD)?
2. How is sialadenitis typically managed initially in Sjogren’s disease?

Learning Objectives

Rows	Poor	Fair	Good	Very Good	Excellent
Discuss the updated understanding of pathophysiology, screening, diagnosis, and therapeutic targets of Sjögren’s disease
Analyze the most up to date evidence for B-cell depleting therapies, including that of a novel dual mechanism B-cell depletor and BAFF-R inhibitor, to improve the management of patients with Sjögren’s disease
Review the potential role of disease-modifying therapy (DMT) with novel B-cell depleting and dual mechanism therapies to improve patient quality of life and reduce disease burden in Sjögren’s disease

Do you feel this activity was fair balanced and free of commercial bias?
If no, please explain:
This educational activity will result in a change in my role as a healthcare team member.
This educational activity will result in a change in my practice behavior.
Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
What factors beyond clinical care that effect the health of your patients does your team experience?
Date
Course Title
Credits
Attestation to time spent on activity:

AcademicCME designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credits™, 0.50 CNE Contact Hours (Provider #P0491) or 0.50 CPE Contact Hours (0.05 CEUs) UAN#JA4008190-0000-26-006-L01-P.
Please select your credit type from the below:
AcademicCME thanks you for your participation in this activity. All information provided improves the scope and purpose of our programs.
Should be Empty: